Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects With Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Conditions
Interventions
Galinpepimut-S
Azacitidine
+6 more
Locations
73
United States
O'Neal Comprehensive Cancer Center
Birmingham, Alabama, United States
UCLA Medical Hematology and Oncology
Los Angeles, California, United States
The Oncology Institute of Hope and Innovation
Whittier, California, United States
Colorado Blood Cancer Institute - SCRI - PPDS
Denver, Colorado, United States
Mayo Clinic Jacksonville Florida
Jacksonville, Florida, United States
Augusta University
Augusta, Georgia, United States
Start Date
February 8, 2021
Primary Completion Date
December 1, 2025
Completion Date
December 1, 2026
Last Updated
October 1, 2025
NCT05564390
NCT03050268
NCT07320235
NCT06782542
NCT06439199
NCT05886049
Lead Sponsor
Sellas Life Sciences Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions